SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Wang, Pengfei; Liu, Lihong; Nair, Manoj S.; Yin, Michael T.; Luo, Yang; Wang, Qian; Yuan, Ting; Mori, Kanako; Solis, Axel Guzman; Yamashita, Masahiro; Garg, Ankur; Purpura, Lawrence J.; Laracy, Justin C.; Yu, Jian; Joshua-Tor, Leemor; Sodroski, Joseph; Huang, Yaoxing; Ho, David D.
• Is Part Of: Emerging microbes & infections. Volume 9:Issue 1(2020)
• Page Start: 2091
• Page End: 2093
• Publication Date: 2020-01-01
• Subjects: SARS-CoV-2 -- antibody -- neutralization -- severe -- non-severe; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2020.1823890
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.